Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR: Best practices in global flow cytometry quality control and harmonization 16 days 4 hours 53 mins 42 secs REGISTER NOW

Emerging immuno-oncology therapies

19 Jul 2018
General interest

Current methods for the treatment of cancer include radiation, chemotherapy and surgical intervention, but alternative treatment modalities exist should these traditional methods prove unsuccessful. In this blog post, Dominic Warrino (KCAS; KS, USA), shares his insights into immuno-oncology, and discusses two case studies utilizing antibody drug conjugates and cellular therapies.

Click here to read the full blog post.

LB_Q3-spotlight-view

Top content

  • Stories, resources and communities to explore for International Day of Women and Girls in Science 2026
  • SCIEX integrates the Echo MS+ system with the ZenoTOF 8600 system
  • Biomarkers without borders: uncovering ancestry and immune response links

Related tags

cancer immuno-oncology protein
Previous article Next article

Related articles

1 JUN 2015 GENERAL INTEREST
First microfluidic device capable of capturing clusters of circulating tumor cells developed
17 JUN 2015 LBA
Fluorescence-based technique developed for protein analysis in tissues
11 AUG 2015 CLINICAL
Biotransformation and stability of antibody–drug conjugates: payload metabolism and linker cleavage delineation
22 OCT 2021 CONFERENCE REPORTS
Highlights: AAPS 2021 PharmSci 360 conference report
19 JUL 2023 NEWS
How patients are being put first in a new era of ‘common sense oncology’
6 FEB 2019 INTERVIEWS
An author’s perspective: Zhengqi Ye on approaches to measure protein binding of enzymatically unstable compounds
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone